ATE152355T1 - Rekombinante herpes simplex virus impfstoffe und methoden - Google Patents

Rekombinante herpes simplex virus impfstoffe und methoden

Info

Publication number
ATE152355T1
ATE152355T1 AT91918320T AT91918320T ATE152355T1 AT E152355 T1 ATE152355 T1 AT E152355T1 AT 91918320 T AT91918320 T AT 91918320T AT 91918320 T AT91918320 T AT 91918320T AT E152355 T1 ATE152355 T1 AT E152355T1
Authority
AT
Austria
Prior art keywords
herpes simplex
simplex virus
methods
virus vaccines
recombinant herpes
Prior art date
Application number
AT91918320T
Other languages
English (en)
Inventor
Bernard Roizman
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24318537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE152355(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE152355T1 publication Critical patent/ATE152355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91918320T 1990-09-10 1991-09-10 Rekombinante herpes simplex virus impfstoffe und methoden ATE152355T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/579,834 US5328688A (en) 1990-09-10 1990-09-10 Recombinant herpes simplex viruses vaccines and methods

Publications (1)

Publication Number Publication Date
ATE152355T1 true ATE152355T1 (de) 1997-05-15

Family

ID=24318537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91918320T ATE152355T1 (de) 1990-09-10 1991-09-10 Rekombinante herpes simplex virus impfstoffe und methoden

Country Status (11)

Country Link
US (2) US5328688A (de)
EP (1) EP0500917B1 (de)
JP (1) JP3334876B2 (de)
AT (1) ATE152355T1 (de)
AU (1) AU658838B2 (de)
CA (1) CA2072627C (de)
DE (1) DE69125925T2 (de)
DK (1) DK0500917T3 (de)
ES (1) ES2102409T3 (de)
GR (1) GR3024144T3 (de)
WO (1) WO1992004050A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
ATE228570T1 (de) * 1992-03-31 2002-12-15 Arch Dev Corp Behandlung von tumorerkrankungen mit modifiziertem hsv
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
EP0675962B1 (de) * 1992-12-23 2003-02-05 Arch Development Corporation Synthetische promotoren von herpes simplex virus
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
AU7014896A (en) * 1995-09-11 1997-04-01 Aviron Methods and compositions for treatment of hsv-2 infections and conditions
DE69722608T2 (de) * 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6509020B1 (en) 1997-03-27 2003-01-21 The University Of Cincinnati Replication-competent herpes simplex virus
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
EP2386629A1 (de) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidinkinasemutanten und Fusionsproteine mit Thymidinkinase- und Guanylatkinaseaktivität
US6051385A (en) * 1997-10-22 2000-04-18 The Regents Of The University Of Michigan Compositions and methods for identifying and testing therapeutics against HSV infection
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
JP2003535565A (ja) * 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
ATE402713T1 (de) * 1999-02-05 2008-08-15 Arch Dev Corp Genetisch manipulierte herpesviren zur behandlung von tumoren
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
ES2286029T3 (es) 1999-07-07 2007-12-01 Zymogenetics Inc Receptor de citocina humano.
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
ATE312189T1 (de) * 2000-01-21 2005-12-15 Biovex Ltd Virusstämme für die onkolytische behandlung von krebs
JP4981229B2 (ja) * 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
US6516246B2 (en) * 2000-09-11 2003-02-04 Mimicking Man Manually, Inc. Method and system for determining native neurological dominant hemisphere
JP4004952B2 (ja) 2000-11-28 2007-11-07 ザ ユニヴァーシティ オヴ シカゴ 心血管疾患治療のための遺伝的に操作されたヘルペスウイルス
KR101021124B1 (ko) 2001-05-24 2011-03-14 지모제넥틱스, 인코포레이티드 Ｔａｃｉ-면역글로불린 융합 단백질
EP1487983A4 (de) * 2002-03-01 2007-08-15 Sloan Kettering Inst Cancer Verhinderung des wiederauftretens und der metastasierung von krebs
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2007068784A1 (en) 2005-12-14 2007-06-21 Licentia Ltd Novel neurotrophic factor protein and uses thereof
WO2004026265A2 (en) * 2002-09-23 2004-04-01 Macrogenics, Inc. Compositions and methods for treatment of herpesvirus infections
JP2006500062A (ja) * 2002-09-27 2006-01-05 パウダージェクト リサーチ リミテッド 遺伝子発現のための核酸構築物
EP1549339B1 (de) * 2002-10-07 2019-06-05 University Of Chicago Targeting von herpes simplex virus an spezifische rezeptoren
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
US7592169B2 (en) * 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
EP1670415A4 (de) * 2003-09-12 2007-12-05 Vertex Pharma Tiermodell für die proteaseaktivität und leberschäden
US7897146B2 (en) * 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
FI20050753A (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
WO2006101629A2 (en) 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
WO2007016239A2 (en) * 2005-07-29 2007-02-08 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
EP1919944B1 (de) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
WO2008141151A2 (en) * 2007-05-09 2008-11-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JP2011526916A (ja) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
EP2710037B1 (de) 2011-05-19 2019-07-31 The Regents of The University of Michigan Alpha-2-integrin-bindemittel und verwendung zur hemmung der krebszellenproliferation
DK2751279T3 (da) 2011-08-31 2017-11-20 St Jude Children's Res Hospital Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
WO2013079687A1 (en) 2011-11-30 2013-06-06 The Chancellor, Masters And Scholars Of The University Of Oxford Inkt cell modulators and methods of using the same
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
JP2015516400A (ja) 2012-04-24 2015-06-11 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ 侵襲的かつ多剤耐性の病原体に対するパーフォリン２の防御
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
WO2014039916A1 (en) 2012-09-06 2014-03-13 The University Of Chicago Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
CN105722509A (zh) 2013-10-09 2016-06-29 迈阿密大学 作为感染性疾病和肠道炎症的药物靶标的穿孔蛋白-2活化剂和抑制剂
TN2017000427A1 (en) 2015-04-08 2019-04-12 Univ Northwestern Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
CN109153977B (zh) 2016-01-08 2022-11-01 雷普利穆内有限公司 溶瘤病毒株
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) * 1986-04-29 1991-03-12 Novagene, Inc. Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form

Also Published As

Publication number Publication date
EP0500917B1 (de) 1997-05-02
CA2072627A1 (en) 1992-03-11
JPH05503017A (ja) 1993-05-27
AU8741891A (en) 1992-03-30
DK0500917T3 (da) 1997-10-27
EP0500917A1 (de) 1992-09-02
JP3334876B2 (ja) 2002-10-15
GR3024144T3 (en) 1997-10-31
CA2072627C (en) 2003-12-16
DE69125925T2 (de) 1997-09-25
ES2102409T3 (es) 1997-08-01
EP0500917A4 (en) 1993-02-17
AU658838B2 (en) 1995-05-04
WO1992004050A1 (en) 1992-03-19
DE69125925D1 (de) 1997-06-05
US6120773A (en) 2000-09-19
US5328688A (en) 1994-07-12

Similar Documents

Publication Publication Date Title
ATE152355T1 (de) Rekombinante herpes simplex virus impfstoffe und methoden
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
DK0595873T3 (da) Negativt cytosindeaminaseselektionssystem til gentransferteknikker og -terapier
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
DE69114997D1 (de) Von Adeno-assoziierte Viren rekombinante Vektoren.
AU6861487A (en) Recombinant herpes simplex viruses, vaccines and methods
IE802225L (en) Vaccine stabilizer
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
ES8504254A1 (es) Procedimiento para obtener un polipeptido
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
DK498387A (da) Virus-dna-sekvens
MX9602256A (es) Vacuna contra la enfermedad de marek.
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
NZ242641A (en) Herpesvirus particles lacking a capsid and viral dna and viral preparations containing them
FR2580176B1 (fr) Vaccin antirabique avirulent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee